← Human Trials & Peer-Reviewed Studies
High-sensitivity Troponin T in hemodialysis patients: a randomized placebo-controlled sub-study investigating angiotensin-II-blockade, variation over time and associations with clinical outcome.
Plain-language guide to PMID 33115436 (2020): double-blind randomized controlled trial of Angiotensin II in 81 patients.
Key Facts
- PMID
- 33115436
- Journal
- BMC nephrology
- Year
- 2020
- Study type
- Randomized Controlled Trial
- Authors
- Peters CD et al. (6 authors)
- DOI
- 10.1186/s12882-020-02103-1
- Registered trial
- NCT00791830
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Angiotensin II.
Troponin T (TnT) is a well-known risk factor for negative outcome in hemodialysis (HD) patients, but little is known about variation over time, and the impact of clinical and dialysis specific factors.
This study investigated the effect of angiotensin II receptor blockade (ARB), short and long-term variation in TnT and associations with clinical parameters.
Who Took Part
According to the abstract, 81 patients were involved.
By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
The patients were allocated by chance, so the Angiotensin II group and the comparison group should start out alike.
As a double-blind Angiotensin II study, the assignments were hidden from both participants and investigators until the end.
The comparison arm used a placebo, so changes seen with Angiotensin II could be set against what happens without it.
What Was Measured
Troponin T (TnT) is a well-known risk factor for negative outcome in hemodialysis (HD) patients, but little is known about variation over time, and the impact of clinical and dialysis specific factors.
PubMed files the paper under topics including Angiotensin-Converting Enzyme Inhibitors, Anti-Inflammatory Agents, Non-Steroidal, Aspirin, Biomarkers, Cardiovascular Diseases, Irbesartan and Kidney Failure, Chronic.
Author keywords: Angiotensin II blockade, Hemodialysis, Randomized controlled trial, Troponin T and Variation.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Angiotensin II in 81 patients.
Results are reported in around 14 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2020 (BMC nephrology), a journal based in England.
More context: the Angiotensin II compound page, all human trials.
Our Notes on the Compound
Angiotensin II: An 8-amino-acid hormone that narrows blood vessels; synthetic angiotensin II (Giapreza) is used for low blood pressure in shock.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.